bempegaldesleukin + pembrolizumab + chemotherapy

This is a combination regimen of **bempegaldesleukin** (also known as NKTR-214 or BEMPEG), **pembrolizumab** (a PD-1 inhibitor), and chemotherapy agents (such as carboplatin, cisplatin, pemetrexed, nab-paclitaxel, or paclitaxel). - Bempegaldesleukin is an investigational, pegylated IL-2 cytokine prodrug that selectively activates and expands CD8+ T cells and NK cells via CD122 (IL-2Rβ), leading to an enhanced anti-tumor immune response with preferential promotion of effector T cells over regulatory T cells. - Pembrolizumab is a monoclonal antibody targeting programmed death receptor 1 (PD-1) and acts as a checkpoint inhibitor to restore anti-tumor T cell function. - Chemotherapy here refers to standard antineoplastic agents (e.g., platinum-based chemotherapy, taxanes, pemetrexed) used in NSCLC and other advanced solid tumors, with direct cytotoxicity against rapidly dividing tumor cells. This combination is under clinical investigation for first-line and subsequent therapy in advanced or metastatic solid tumors, most notably non-small cell lung cancer (NSCLC). The regimen is being studied for synergistic efficacy and tolerability in immuno-oncology contexts.

Other names

BEMPEG + pembrolizumab + chemotherapy